Special Issue

Advances in Diagnosis and Treatment of Pancreatic Cancer

Message from the Guest Editors

Pancreatic ductal adenocarcinoma (PDAC) remains a devastating disease. Due to unspecific symptoms in its early stages and the absence of reliable diagnostic markers for early detection, PDAC often remains undiagnosed until late in the disease. In cases of invasion of the surrounding major visceral blood vessels or systemic spread, upfront surgery is often not possible or indicated. In some patients, modern (radio-) chemotherapy regimens may downstage the disease and facilitate the resectability of initially unresectable tumors (conversion surgery). For a large percentage of patients with progressed and/or metastatic disease, several novel (personalized) treatment strategies are currently being investigated. Improvements in histopathological and molecular tissue analysis, radiological imaging and image analysis as well as improved knowledge of radio-pathological correlation help to tailor these novel therapies to the individual patient. We invite original research and review articles focusing on advances in radiological, histopathological, molecular, and genomic diagnostics as well as medical and surgical therapy of pancreatic cancer.

Guest Editors

Prof. Dr. Matthias Gaida

Institute for Pathology, University Medical Center Mainz, 55131 Mainz, Germany

Dr. Philipp Mayer

Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany

Deadline for manuscript submissions

closed (30 June 2023)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/101518

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/ cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

